NASDAQ · ILMNHealthcareLab Analytical Instruments

Illumina financials

$273.68+0.62%
Close Sep 30, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 28
FY24
Dec 29
FY23
Dec 31
FY22
Jan 1
FY21
Jan 2
FY20
Jan 3
FY19
Dec 29
FY18
Dec 30
FY17
Dec 31
FY16
Jan 1
Revenue$4.34B$4.37B$4.50B$4.58B$4.53B$3.24B$3.54B$3.33B$2.75B$2.40B
Gross profit$2.87B$2.86B$2.74B$2.97B$3.15B$2.20B$2.47B$2.30B$1.83B$1.67B
Gross margin66.1%65.4%60.9%64.8%69.7%68.0%69.6%69.0%66.4%69.5%
Operating income$807.0M-$833.0M-$1.07B-$4.18B-$123.0M$580.0M$985.0M$883.0M$606.0M$587.0M
Net income$850.0M-$1.22B-$1.16B-$4.40B$762.0M$656.0M$1.00B$826.0M$726.0M$454.0M
Net margin19.6%−28.0%−25.8%−96.1%16.8%20.3%28.3%24.8%26.4%18.9%
Diluted EPS$5.45$-7.69$-7.34$-28.00$5.04$4.45$6.73$5.54$4.92$3.07
EBITDA$1.09B$954.0M$210.0M$748.0M$128.0M$767.0M$1.17B$1.06B$762.0M$719.0M
Operating cash flow$1.08B$837.0M$478.0M$392.0M$545.0M$1.08B$1.05B$1.14B$875.0M$779.0M
Free cash flow$931.0M$709.0M$283.0M$106.0M$337.0M$891.0M$842.0M$846.0M$565.0M$519.0M
Diluted shares156.0M159.0M158.0M157.3M151.0M147.4M149.0M149.0M148.0M148.0M

Balance sheet

Period endDec 28Dec 29Dec 31Jan 1Jan 2Jan 3
Cash & equivalents$1.42B$1.13B$1.05B$2.01B$1.23B$1.81B
Short-term investments$215.0M$93.0M$6.0M$26.0M$107.0M$1.66B
Total debt$1.99B$1.99B$1.49B$2.73B$1.70B$1.18B
Total assets$6.64B$6.30B$10.11B$12.25B$15.22B$7.58B
Total liabilities$3.92B$3.93B$4.37B$5.65B$4.48B$2.89B
Shareholders' equity$2.72B$2.37B$5.75B$6.60B$10.74B$4.69B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology